Rexahn Pharmaceuticals ( Rexahn Pharmaceuticals)

Primary tabs

Rexahn Pharmaceuticals's picture

Management

Contact Address

About Rexahn Pharmaceuticals

Rexahn’s goal is to be a world leader in the discovery and development of new drugs to treat cancer. By developing compounds which specifically target cancer cells, but not healthy tissue, Rexahn’s drug candidates may demonstrate increased efficacy and reduced toxicity, efficacy against multiple drug resistant cancer cells and synergism with existing cytotoxic compounds. Utilizing a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling, nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Rexahn Pharmaceuticals press release, blog etc

Thu, 06/17/2021 - 01:55 Processa Pharmaceuticals Enters Into A Licensing Agreement With Ocuphire Pharma, Inc., For The Development Of RX-3117
Tue, 03/09/2021 - 23:09 Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update
Tue, 11/10/2020 - 09:01 Ocuphire to Participate in Upcoming Virtual HCW Conference in November
Fri, 11/06/2020 - 06:19 Industry Veteran Susan Benton Joins the Ocuphire Pharma Board of Directors
Wed, 11/04/2020 - 23:01 Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
Mon, 11/02/2020 - 12:41 Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma
Wed, 09/09/2020 - 14:48 Ocuphire to Participate in Upcoming Virtual Healthcare Investor Conferences in September
Fri, 07/03/2020 - 15:51 Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals
Tue, 09/24/2019 - 12:06 Rexahn to Explore Strategic Alternatives
Mon, 05/27/2019 - 20:46 Rexahn Announces Move to Nasdaq
Tue, 04/16/2019 - 13:09 Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China
Fri, 04/12/2019 - 06:10 Rexahn Effects 1-for-12 Reverse Stock Split
Tue, 04/09/2019 - 21:19 Rexahn Announces Reverse Stock Split
Tue, 03/26/2019 - 20:53 Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting
Thu, 03/07/2019 - 20:35 Rexahn Pharmaceuticals Reports 2018 Financial Results
Sun, 03/03/2019 - 20:40 Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE in First-line Metastatic Pancreatic Cancer Patients
Thu, 02/28/2019 - 19:03 Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
Mon, 02/18/2019 - 19:54 Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium